GLP-1 in Chronic Rhinosinusitis and Nasal Polyps: Dupixent Stacking Evidence

Chronic rhinosinusitis (CRS) affects roughly 5–12% of adults and the polyp-forming subtype (CRSwNP) is one of the most refractory, steroid-dependent inflammatory diseases in otolaryngology. Obesity is a documented risk factor for CRS severity (Bhattacharyya 2013^[7]), which is part of why people on GLP-1 therapy ask whether Wegovy or Zepbound helps their sinuses. The short answer: there is no randomized GLP-1-on-CRS trial, but the mechanism (weight loss plus a documented anti-inflammatory profile, Mehdi 2023^[9]) is plausible, and the biologics that anchor modern CRSwNP care — dupilumab (Dupixent), omalizumab (Xolair), and mepolizumab (Nucala) — have no pharmacokinetic interaction with subcutaneous GLP-1 agonists. This article walks through the CRS guidelines, the biologic data, the FESS pathway, and what the stacking decision actually looks like in practice.

The honest summary

• CRS is two diseases, not one. CRSwNP (with nasal polyps) is driven by type 2 inflammation — IL-4, IL-5, IL-13, IgE — and responds to the biologics below. CRSsNP (without polyps) is more heterogeneous and managed primarily with saline, intranasal steroids, and short macrolide courses per the AAO-HNS and EPOS guidelines (Rosenfeld 2015^[4], Fokkens 2020^[5]).
• Three biologics are FDA-approved for severe CRSwNP. Dupilumab (Bachert 2019 SINUS-24 / SINUS-52^[1]) produced roughly −19 points of SNOT-22 vs placebo at 24 weeks. Omalizumab (Gevaert 2020 POLYP-1 / POLYP-2^[2]) produced about −16. Mepolizumab (Han 2021 SYNAPSE^[3]) produced about −16. All three reduce polyp size and rescue-surgery rates.
• FESS is still standard for refractory disease. Endoscopic sinus surgery remains the reference intervention for patients failing medical therapy; published SNOT-22 changes are in the −20 to −30 range and benefit is durable for 3–5 years.
• GLP-1 stacking is mechanistically safe. Subcutaneous biologics, intranasal steroids, and systemic corticosteroid bursts do not share metabolic pathways with GLP-1 receptor agonists. Continue all CRS therapy when starting Wegovy or Zepbound.

What CRS is and how it is diagnosed

Both the AAO-HNS adult sinusitis guideline (Rosenfeld 2015^[4]) and the European EPOS 2020 position paper (Fokkens 2020^[5]) define chronic rhinosinusitis as ~12 weeks of two or more cardinal symptoms — nasal obstruction, anterior or posterior drainage, facial pressure or pain, and reduced sense of smell — confirmed by objective inflammation on nasal endoscopy or CT imaging. Polyps are visible on endoscopy and define the CRSwNP phenotype. The Lund-Mackay CT score (0–24, scored across the six paired sinuses plus the ostiomeatal complex) is the radiographic standard. SNOT-22 (Sinonasal Outcome Test, 22 items, 0–110 points; minimal clinically important difference ~8.9) is the patient-reported outcome that anchors every modern trial.

Phenotype matters because treatment diverges sharply. Roughly 80% of CRSwNP cases in Western populations are type-2 high (eosinophilic, IL-4 / IL-5 / IL-13 / IgE driven) and about half have comorbid asthma. CRSsNP is more heterogeneous: some patients have type-1 or type-3 inflammation that responds to macrolides; others fall on the type-2 spectrum and overlap clinically with mild CRSwNP. Aspirin-exacerbated respiratory disease (AERD, also known as Samter triad — the combination of CRSwNP, asthma, and NSAID hypersensitivity) is a particularly steroid-dependent subgroup that responds well to dupilumab.

The medical management ladder

Both guidelines^[4][5] recommend the same first-line stack:

• High-volume saline irrigation — 240 mL of isotonic or hypertonic saline via a squeeze bottle or neti pot, 1–2 times daily. The single most cost- effective intervention; reduces SNOT-22 in nearly every trial that included it as a control.
• Intranasal corticosteroids — fluticasone propionate (Flonase), mometasone furoate (Nasonex), or budesonide (often used off-label as a saline-bottle additive at 0.5 mg per 240 mL). Daily, indefinitely. The first-line anti-inflammatory therapy for both CRS subtypes.
• Short oral corticosteroid bursts — prednisone 30–40 mg daily for 5–10 days for severe flares or pre-operatively to shrink polyps. The burden of repeated bursts in CRSwNP is substantial — Peters / Pinto 2025^[6] quantified the cumulative bone, glycemic, and cardiovascular costs and framed steroid-sparing biologics as the response.
• Macrolide antibiotics — low-dose clarithromycin or azithromycin for 8–12 weeks is an option for select CRSsNP patients with neutrophilic inflammation; less useful in CRSwNP.
• Leukotriene receptor antagonists (montelukast) have a small effect on polyp-related symptoms and are generally reserved for AERD patients who tolerate them.

The biologic era for severe CRSwNP

Three monoclonal antibodies are FDA-approved for severe, inadequately-controlled CRSwNP. All three are subcutaneous and target the type-2 pathway:

Dupilumab (Dupixent) blocks the shared IL-4 receptor alpha subunit, neutralizing IL-4 and IL-13 signaling. The pivotal LIBERTY NP SINUS-24 and SINUS-52 trials (Bachert 2019 Lancet^[1]) randomized 724 adults with severe CRSwNP to dupilumab 300 mg every 2 weeks or placebo on top of background mometasone. At week 24, SNOT-22 fell by roughly −19 points more on dupilumab than placebo, nasal polyp score fell by ~−2 points, and Lund-Mackay CT score fell by ~−7 points. Need for rescue sinus surgery was reduced by ~83% over 52 weeks. Dupilumab also showed concurrent benefit in comorbid asthma.

Omalizumab (Xolair) binds free IgE and was the first biologic with phase-3 CRSwNP data. POLYP-1 and POLYP-2 (Gevaert 2020 J Allergy Clin Immunol^[2]) randomized 265 adults to omalizumab dosed by weight and baseline IgE every 2–4 weeks vs placebo on top of intranasal mometasone. SNOT-22 improved by roughly −16 more on omalizumab, with parallel reductions in polyp score and need for systemic corticosteroids. The dose is the same weight-and-IgE table used in allergic asthma.

Mepolizumab (Nucala) blocks IL-5 and depletes eosinophils. The SYNAPSE phase-3 trial (Han 2021 Lancet Respir Med^[3]) randomized 414 adults with severe CRSwNP and prior surgery to mepolizumab 100 mg every 4 weeks vs placebo. SNOT-22 improved by ~−16 more on mepolizumab, nasal polyp score fell by ~−1 point, and need for repeat sinus surgery was reduced by ~57%. Benralizumab (Fasenra, anti-IL-5R) was studied in CRSwNP (the OSTRO program) but its CRSwNP data have been substantially weaker than the SYNAPSE result for mepolizumab; payor coverage in CRSwNP is uneven.

FESS: when surgery is the answer

Functional endoscopic sinus surgery remains the reference intervention when maximal medical therapy plus, where appropriate, biologic therapy fails to control symptoms or polyp burden. A standard FESS opens the ethmoid cells and widens the maxillary, frontal, and sphenoid sinus outflow, allowing topical steroid irrigations to reach the previously-inflamed mucosa. Published SNOT-22 changes after FESS are in the −20 to −30 range — consistently larger in single-arm series than any medical intervention — with durable benefit at 3–5 years.

Cost matters in the decision. A primary FESS in the United States is roughly $10,000–$20,000 all-in (facility, surgeon, anesthesia); annual dupilumab or omalizumab therapy runs roughly $40,000–$60,000 at list price before rebates. Insurance prior authorization for any of the three biologics generally requires documented failure of intranasal corticosteroids, at least one course of systemic corticosteroids in the prior 2 years, and either prior FESS or contraindication to surgery.

Where GLP-1 therapy fits

There is no randomized trial of semaglutide or tirzepatide as a CRS-modifying therapy and we do not pretend otherwise. Two mechanistic threads support the question:

First, obesity is associated with worse sinonasal outcomes. Bhattacharyya 2013 (Laryngoscope^[7]) analyzed a large US claims sample and found higher rates of chronic rhinosinusitis and other inflammatory sinonasal disorders in adults with obesity. A separate Korean pediatric analysis (Kim 2013 Laryngoscope^[8]) reported parallel associations between obesity and CRS, allergic rhinitis, and acute otitis media in school-age children. The magnitude is modest but consistent across populations: weight loss plausibly removes one upstream driver of severity.

Second, GLP-1 receptor agonists have documented anti-inflammatory effects beyond glycemic control. Mehdi 2023 (Front Immunol^[9]) reviewed the immunomodulatory profile of GLP-1: reductions in pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1-beta), a modulating effect on T-cell subsets, and downstream effects on adipose-tissue macrophages. The relevance to type-2 sinonasal disease is indirect — the mechanistic data are mostly cardiovascular and hepatic — but the anti-inflammatory direction is consistent.

The honest framing for a patient: starting Wegovy or Zepbound is unlikely to be a primary CRS therapy, but is unlikely to make CRS worse, and the comorbid-asthma benefits documented in the GLP-1 pulmonary literature likely carry over to the substantial CRSwNP-asthma overlap (~50% of CRSwNP patients have concurrent asthma).

Magnitude: SNOT-22 score change at 24 weeks by intervention

The interaction question, drug by drug

• Intranasal corticosteroids (fluticasone, mometasone, budesonide). Local action, negligible systemic absorption at recommended doses, no GLP-1 PK interaction. Continue indefinitely on Wegovy or Zepbound.
• Saline irrigation. Mechanical, no interaction. Hydration emphasis matters more on a GLP-1 because nausea-driven dehydration is the most common early side effect; see our GLP-1 first 30 days survival guide for fluid targets.
• Oral corticosteroid bursts. Prednisone is metabolized hepatically (CYP3A4); GLP-1 agonists do not induce or inhibit CYP3A4 meaningfully. The clinically relevant interaction is the opposite direction — steroid-induced hyperglycemia can briefly worsen glycemic control in patients also taking a GLP-1 for diabetes. Monitor finger-stick glucose during bursts.
• Biologics (dupilumab, omalizumab, mepolizumab, benralizumab). All subcutaneous monoclonal antibodies, cleared by reticuloendothelial proteolysis, not hepatic CYPs. No PK interaction with semaglutide, tirzepatide, or oral semaglutide.
• Macrolides (clarithromycin, azithromycin). Clarithromycin is a strong CYP3A4 inhibitor and a mild QT-prolonging agent; the GLP-1 piece is unaffected but the patient’s other medications may need review.
• Leukotriene receptor antagonists (montelukast). Hepatic metabolism (CYP2C8 / 3A4); no documented GLP-1 interaction.

The practical workflow

1. Confirm the CRS phenotype with an ENT. Nasal endoscopy plus CT sinuses (Lund-Mackay score) is the diagnostic floor. Allergy / immunology consultation is appropriate for any patient with comorbid asthma or suspected AERD.
2. Optimize the medical floor. Daily high-volume saline irrigation plus a daily intranasal corticosteroid. SNOT-22 at baseline; repeat at 8–12 weeks.
3. Escalate by phenotype. CRSwNP failing maximal medical therapy: discuss biologic vs FESS. CRSsNP: consider a macrolide course; FESS for refractory disease.
4. Start the GLP-1 in parallel if indicated. Stable CRS on a working regimen plus obesity meeting GLP-1 criteria: viable. Continue all CRS therapy. Track SNOT-22 alongside weight at each titration step.
5. Re-evaluate at 6 months. Compare SNOT-22 and weight trajectory. If SNOT-22 has improved on the combination, that is a meaningful real-world signal even without a randomized trial.

Special populations

Pediatric patients. Pediatric CRSwNP is rare and usually associated with cystic fibrosis or primary ciliary dyskinesia. GLP-1 agonists are approved only in adolescents age ≥ 12 for obesity (liraglutide, semaglutide); CRS management in this population follows the pediatric ENT pathway and is not modified by GLP-1 therapy.

Pregnancy. GLP-1 receptor agonists are not recommended during pregnancy and should be stopped at least 2 months before conception. CRS care continues unchanged — intranasal corticosteroids are pregnancy-compatible and biologics are individualized with maternal-fetal medicine input.

Insurance. CRS medical care is universally covered. Biologic prior authorization requires documented failure of standard therapy. FESS is covered when medical therapy fails. GLP-1 coverage for obesity remains payor- and plan-specific and is independent of the CRS workup.

Related research

• GLP-1 in asthma and COPD — the pulmonary companion article; ~50% of CRSwNP patients have concurrent asthma
• GLP-1, allergic rhinitis, and immunotherapy — antihistamine, SLIT, and anti-IgE biologic interactions
• GLP-1, psoriasis, and biologic / TNF-inhibitor stacking — the biologic-stacking adjacency for type-2 inflammatory disease
• GLP-1, tinnitus, and otolaryngology — ENT-side companion article
• GLP-1 first 30 days survival guide — hydration and side-effect management while continuing CRS therapy

Important disclaimer. This article is educational and does not constitute medical advice. CRS diagnosis requires nasal endoscopy or CT imaging by a qualified clinician; biologic therapy decisions are made with allergy / immunology or ENT specialists. The GLP-1 + CRS combination has not been studied in a randomized trial; the practical guidance above reflects mechanism plus the absence of documented pharmacokinetic interactions, not evidence of a CRS-specific treatment effect from GLP-1 therapy. PMIDs were verified live against the PubMed E-utilities API on 2026-05-30.

Last verified: 2026-05-30. Next review: every 12 months, or sooner if a randomized GLP-1-on-CRS trial, long-term SINUS / SYNAPSE / POLYP extension data, or a new biologic FDA approval changes the standard of care.